A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
Vermorken, J.B., Rottey, S., Ehrnrooth, E., Pelling, K., Lahogue, A., Wind, S., Machiels, J.-P.
Published in Annals of oncology (01.05.2013)
Published in Annals of oncology (01.05.2013)
Get full text
Journal Article
1204 ORAL A Phase lb Open-label Study to Assess Continuous Oral Treatment With Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens – Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With Advanced Solid Tumours
Vermorken, J, Rottey, S, Ehrnrooth, E, Pelling, K, Lahogue, A, Machiels, J
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours
Nysom, K., Leblond, P., Frappaz, D., Aerts, I., Varlet, P., Giangaspero, F., Gambart, M., Hargrave, D., Marshall, L., Kearns, P., Makin, G., Gallego, S., Kieran, M., Casanova, M., Lahogue, A., Wind, S., Stolze, B., Roy, D., Uttenreuther-Fischer, M., Geoerger, B.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors
Vermorken, J. B., Machiels, J. H., Rottey, S., Thurm, H. C., Pelling, K., Lahogue, A.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment
Xu, B, Im, S-A, Huang, C-S, Im, Y-H, Ro, J, Zhang, Q, Arora, R, Mehta, A, Jung, K, Yeh, D-C, Lee, S, Jassem, J, Wojtukiewicz, M, Chen, S-C, Lahogue, A, Uttenreuther-Fischer, M, Hurvitz, S-A, Harbeck, N, Piccart-Gebhart, M
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article
BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor for the Treatment of Patients with HER2-Negative Metastatic Breast Cancer after Failure of No More Than Two Prior Chemotherapies
Harbeck, N., Schmidt, M., Harter, P., Possinger, K., Jonat, W., Lück, H., Beckmann, M., Fasching, P., Schütte, J., Solca, F., Uttenreuther-Fischer, M., Taton, M., Lahogue, A., Awada, A., De Grève, J., Canon, J., Dirix, L., Fleischer, F., Neven, P., Gottschalk, N., Piccart, M., Schuler, M.
Published in Cancer research (Chicago, Ill.) (15.12.2009)
Published in Cancer research (Chicago, Ill.) (15.12.2009)
Get full text
Journal Article